LOTEMAX SM

Bausch + Lomb pioneered the development of the loteprednol etabonate molecule allllll the way back in 1991 when I was just a pup. 7 years later, they launched their very first formulation, Lotemax Suspension. Over the next 10+ years, they’d launch two more and in 2019, they trusted me and my team to launch their most advanced formulation yet, Lotemax SM.

20+ years is a long time to build a reputation and following. Although Lotemax became a mainstay among eye doctors, it was also perceived as a “soft steroid.” In this largely HCP-focused launch, we were tasked with acknowledging the legacy of the brand while showcasing the new innovations of Lotemax SM to prove to doctors it could get the job done after all eye surgeries.

It was no small task and we delivered a mighty effort which included a robust website, videos, digital and printed sales aids, journal ads, and a whole lot more.

HCP pieces

patient pieces

We did a patient website, the beginner’s brochure below, and few others, all of which steered clear of the HCP concept.